瑞舒伐他汀对2型糖尿病视网膜病变患者血清PEDF、IL-6水平的影响

Influence of Rosuvastatin on Serum Pigment Epithelium Derived- factor,Interleukin- 6 in Patients with Type 2 Diabetic Retinopathy

目的探讨瑞舒伐他汀对2型糖尿病视网膜病变(DR)患者血清PEDF、IL-6水平的影响。方法选取60例2型糖尿病视网膜病变患者,随机分为实验组(瑞舒伐他汀治疗)30例和空白对照组(仅常规降血糖治疗)30例,疗程为3个月。分析两组患者治疗前后血清PEDF、IL-6、TC、TG、LDL、HDL、FPG、2h PG、Hb A1c水平以及DR分期的变化情况。结果实验组血清IL-6、TC、TG、LDL、FPG、2h PG、Hb A1c水平及DR分期与治疗前比较明显下降,血清PEDF、HDL水平与治疗前比较明显升高,差异均有统计学意义(P<0.01)。空白对照组中FPG、2h PG、Hb A1c水平较治疗前明显下降(P<0.01),其余各指标与治疗前比较,差异均无统计学意义(P>0.05)。实验组治疗前后的差值(ΔPEDF、ΔIL-6、ΔDR分期、ΔTC、ΔTG、ΔLDL、ΔHDL)与对照组治疗前后的差值比较,差异均有统计学意义(P<0.01)。结论瑞舒伐他汀能显著降低DR患者血清IL-6水平,升高血清PEDF水平,从而延缓了DR患者的病情进展。

Objective To observe the effect of rosuvastatin on serum pigment epithelium derived - factor （ PEDF ）, interleukin - 6 （IL -6） in patients with type2 diabetic retinopathy（ DR ）. Methods We selected 60 piticnts with type 2 diabetic retinopathy who were randomly divided into two groups after three - months long treatments of rosuvastatin （30cases） and blank （30cases, Only hypoglycemic therapy）. Patients before and after treatment were observed for serum PEDF, IL - 6, Total cholesterol（ TC）, Triglyceride （ TG）, Low densi- ty lipoprutein（LDL） ,High density lipoprotein （HDL） ,Fasting plasma glucose （FPG） ,2 - hour postprandial glucose（2hPG） , Glycosylated hemoglobin（HbAlc） and the stages of diabetic retinopathy changes. Results In the experimental group after three - months long treat- ments of rusuvastatin,the content of serum IL- 6,TC ,TG,LDL,FPG,2hPG, HbA1 c and the stages of diabetic retinopathy were decreased significantly compared to the previous （P 〈 0.01 ） ,and the content of serum PEDF,HDL were increased significantly compared to the pre- vious（P 〈0. O1 ）. The blank control group were not given rosuvastatin therapy. After three - months, the content of FPG,2bPG, HbAlc were decreased significantly compared to the previous（P 〈 0.01 ） , other indicators did not alter significantly, and the difference were not statistically significant（P 〉 0.05 ）. The difference between the experimental group before and after treatment （ APEDF, AIL - 6, ADR, ATC, ATG, ALDL, AHDL）compared to the blank control group were statistically significant（ P 〈 0.01 ）. Conclusion Rosuvastatin can re- duce the concentration of serum IL - 6, increase the concentration of serum PEDF, thus delay the progression of diabetic retinopathy.